Now we have to wait and see what the postponement of the quarterly figures means. The buy order was triggered automatically and was actually set at €14.50. Then you wake up and get the news. Let's see what happens.
After I had missed to add some 2 weeks ago, I immediately placed a buy order and this was triggered today. More Daiichi, more Datroway. The reorganization of the Group with the sale of the healthcare division and increased focus on research is just what I need.
After stumbling across the drug Datroway in an internal presentation, I took a closer look at the manufacturer. The result was a profitable BioTech company with a great pipeline, which is already profitable and growing strongly. As a small pearl, there is a small dividend on top.
Mr. Prompt and the dear @Raketentoni confirmed my assessment once again, so I couldn't keep my hands off it today and added it to my portfolio as a satellite.
I was still considering whether it would be the $DSNKY ADR or the original, but GPT convinced me of the original.
Congratulations and I'll post the analysis here again for everyone
He hasn't just dug up any old gaff, but the current "shooting star" of oncology.
Daiichi Sankyo (4568.T). You've done your homework. The story about the breast cancer drug is true. We're talking about Enhertu (trastuzumab deruxtecan). This is the 'gold standard' in the medical community right now. Together with AstraZeneca, they are rolling up the market with it. But as always, a great story does not make a good investment for my portfolio. Let's take a look at the books: 1. the core quality check (growth & substance) The story: Enhertu is a money-printing machine. Sales are growing at double-digit rates, sometimes rapidly. The figures: Daiichi is growing enormously. Sales growth > 20 % is not uncommon here. The operating margin is steadily improving as the high development costs are now bearing fruit. My score: > 35 points. Verdict: Pass with an asterisk. This is extremely high quality. Not a 'biotech gamble', but big pharma in growth mode. 2. the dividend check (the damper) You say: 'There are dividends too'. I say: 'Yes, but it's more of a tip'. The current dividend yield is a meagre ~0.6% to 0.8%. My limit: 3.5 %. Verdict: Failed. 3. the valuation (the price of success) Here I have to raise my finger. Since every analyst knows that Enhertu could become the best-selling drug by 2030, this is already heavily priced into the share price. The P/E ratio is often over 40x. You are already paying today for the success of 2028. If even one small study goes wrong or a patent dispute arises (which is commonplace in the pharmaceutical industry), the share price will plummet. My conclusion for you, @Keineui: You've found an excellent growth company here. If you are looking for price gains and believe in Enhertu's dominance: buy/hold. If you (like me) are looking for cash flow and dividends: Hands off. The yield is too low and the valuation too high. I would tolerate it as an 'aggressive satellite' in the portfolio, but not as a basic investment for retirement. Hilsen from Denmark, Mister Prompt"
$4568 (-1,35 %) together with $AZN (+1,12 %) is currently developing the drug Datroway (breast cancer). Sales revenues of around € 6 billion are expected by 2030:
Are there any $4568 (-1,35 %) Daiichi Sankyo with Trade Republic? I was thinking about possibly adding a savings plan here and have just realized that this doesn't seem to be possible.
Is this normal or is it the same for some people? Or are there possibly other reasons for this?
